Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 224

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering

Open access
Daher, May, Rezvani, Katayoun · 2018 · Current Opinion in Immunology

Abstract

Recent advances in the field of cellular therapy have focused on autologous T cells engineered to express a chimeric antigen receptor (CAR) against tumor antigens. Remarkable responses have been observed in patients receiving autologous CD19- redirected T cells for the treatment B-lymphoid malignancies. However, the generation of autologous products for each patient is logistically challenging and expensive. Extensive research efforts are ongoing to generate an off-the-shelf cellular product for the treatment of cancer patients. Natural killer cells (NK) are attractive contenders since they have potent anti-tumor activity, and their safety in the allogeneic setting obviates the need for an autologous source. In this review, we discuss advantages and limitations of NK cellular therapy, and novel genetic engineering strategies that may be applied to overcome some of the limitations. Next-generation engineered NK cells are showing great promise in the preclinical setting and it is likely that in the next few years CAR- engineered NK cells will be incorporated into the current armamentarium of cell-based cancer therapeutics.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.coi.2018.03.013

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 224

Metadata

Authors
Daher, M., & Rezvani, K.
Venue
Current Opinion in Immunology
Publisher
Elsevier BV
Published
2018-04
Volume
51
Pages
146-153
ISSN
0952-7915 (ISSN-L)
OpenAlex
W2794892435
Cited by
224
References
3
FWCI
3.21
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering. https://app.cochat.ai/papers/10.1016/j.coi.2018.03.013
The paper
Daher, M., & Rezvani, K. (2018). Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering. Current Opinion in Immunology. https://doi.org/10.1016/j.coi.2018.03.013

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.